Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

NCT06260722 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of the medication retatrutide compared to semaglutide in adults with type 2 diabetes who do not have adequate blood sugar control while taking metformin, with or without an SGLT2 inhibitor.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,250 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-02 · est. completion 2027-01

Where 77 sites · Argentina, Canada, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06260722 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC.
Semaglutide Drug

Administered SC.

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06260722 ↗